Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2016

Market: Pharmaceuticals and Healthcare

Global, 132 pages report, published by GlobalData

Keywords : Pharma, Pharmaceuticals, Healthcare, Deal Value, Deal Volume, Private Equity, Venture Capital, Partnership, Licensing, Agreements, North America, Europe, Asia-Pacific, Rest of the World (ROW), Merger, M&A, Acquisition, Equity Offering, Debt Offering, Capital raising, Asset Purchase, Private Placement, Secondary offering, IPO, Initial Public Offer, cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, women's health, Upfront Payment, Milestone Payment, Phases, Clinical Trials

Report ThumbnailJune-2016
Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2016

Summary

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2016” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q1 2016. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the five quarters.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.
  • 1.2 List of Figures
  • Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$m), Q1 2015 - Q1 2016 15
  • Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), Q1 2016 17
  • Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), Q1 2016 18
  • Figure 4: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$m), Q1 2015 - Q1 2016 26
  • Figure 5: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, Q1 2015 - Q1 2016 28
  • Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 29
  • Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$m), , Q1 2015 - Q1 2016 32
  • Figure 8: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 34
  • Figure 9: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), Q1 2016 36
  • Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), Q1 2016 37
  • Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q1 2015 - Q1 2016 38
  • Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 39
  • Figure 13: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 41
  • Figure 14: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q1 2015 - Q1 2016 43
  • Figure 15: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 44
  • Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 46
  • Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), Q1 2015 - Q1 2016 47
  • Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q1 2015 - Q1 2016 50
  • Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q1 2015 - Q1 2016 52
  • Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q1 2015 - Q1 2016 53
  • Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), Q1 2015 - Q1 2016 55
  • Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 57
  • Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2015 - Q1 2016 59
  • Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 62
  • Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2015 - Q1 2016 63
  • Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, Q1 2015 - Q1 2016 65
  • Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), Q1 2015 - Q1 2016 66
  • Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2015 - Q1 2016 68
  • Figure 29: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q1 2015 - Q1 2016 70
  • Figure 30: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q1 2015 - Q1 2016 72
  • Figure 31: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q1 2015 - Q1 2016 73
  • Figure 32: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q1 2015 - Q1 2016 74
  • Figure 33: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q1 2015 - Q1 2016 75
  • Figure 34: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q1 2015 - Q1 2016 76
  • Figure 35: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 77
  • Figure 36: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 81
  • Figure 37: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 84
  • Figure 38: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 88
  • Figure 39: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 91
  • Figure 40: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 94
  • Figure 41: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 98
  • Figure 42: Pharmaceuticals & Healthcare, Global, Hematological Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 101
  • Figure 43: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 104
  • Figure 44: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 107
  • Figure 45: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 110
  • Figure 46: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 113
  • Figure 47: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 118
  • Figure 48: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 121
  • Figure 49: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 124
  • Figure 50: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 126
  • 1.1 List of Tables
  • Table 1: Pharmaceuticals & Healthcare, Global, Deal Summary, Number of Deals and Deal Values (US$m), Q1 2015 - Q1 2016 16
  • Table 2: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), Q1 2016 18
  • Table 3: Pharmaceuticals & Healthcare, Global, Top Deals, Q1 2016 19
  • Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 27
  • Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, Q1 2016 27
  • Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, , Q1 2015 - Q1 2016 28
  • Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2015 - Q1 2016 30
  • Table 8: Pharmaceuticals & Healthcare, Global, Top Initial Public Offering Deals, Q1 2016 30
  • Table 9: Pharmaceuticals & Healthcare, Global, Top Secondary Offering Deals, Q1 2016 31
  • Table 10: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, Q1 2016 31
  • Table 11: Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q1 2015-Q1 2016 32
  • Table 12: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2015 - Q1 2016 33
  • Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 35
  • Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Capital Deals, Q1 2016 35
  • Table 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), Q1 2016 37
  • Table 16: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2015 - Q1 2016 38
  • Table 17: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 39
  • Table 18: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q1 2015 - Q1 2016 40
  • Table 19: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 42
  • Table 20: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, Q1 2016 42
  • Table 21: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2015 - Q1 2016 43
  • Table 22: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 45
  • Table 23: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 46
  • Table 24: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2015 - Q1 2016 47
  • Table 25: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2016 48
  • Table 26: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q1 2016 48
  • Table 27: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q1 2016 49
  • Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q1 2015 - Q1 2016 51
  • Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q1 2015 - Q1 2016 54
  • Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q1 2015 - Q1 2016 56
  • Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 58
  • Table 32: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2015 - Q1 2016 60
  • Table 33: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q1 2016 60
  • Table 34: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q1 2016 61
  • Table 35: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q1 2016 61
  • Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 62
  • Table 37: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (US$ m), Q1 2015 - Q1 2016 64
  • Table 38: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q1 2015 - Q1 2016 67
  • Table 39: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Values (US$ m), Q1 2015 - Q1 2016 69
  • Table 40: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q1 2015 - Q1 2016 71
  • Table 41: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q1 2015 - Q1 2016 72
  • Table 42: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q1 2015 - Q1 2016 73
  • Table 43: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Operating Profit, Q1 2015 - Q1 2016 74
  • Table 44: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q1 2015 - Q1 2016 75
  • Table 45: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q1 2015 - Q1 2016 76
  • Table 46: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 78
  • Table 47: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 82
  • Table 48: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 85
  • Table 49: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 89
  • Table 50: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 92
  • Table 51: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 95
  • Table 52: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 99
  • Table 53: Pharmaceuticals & Healthcare, Global, Hematological Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 102
  • Table 54: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 105
  • Table 55: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 108
  • Table 56: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 111
  • Table 57: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 114
  • Table 58: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 119
  • Table 59: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 122
  • Table 60: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 125
  • Table 61: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 126
  • Table 62: Pharmaceuticals & Healthcare, Deals’ Key Financials, Global Acquisition Deals, Q1 2015-Q1 2016 127
  • 1 Table of Contents
  • 1 Table of Contents 2
  • 1.1 List of Tables 7
  • 1.2 List of Figures 11
  • 2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q1 2016 15
  • 2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q1 2016 15
  • 2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q1 2016 17
  • 2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q1 2016 18
  • 2.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q1 2016 19
  • 2.4.1 Shire to Acquire Baxalta for USD32 Billion 19
  • 2.4.2 Mylan to Acquire Meda for USD9.9 Billion 21
  • 2.4.3 Abbott Labs to Acquire Alere 23
  • 2.4.4 Sanofi Prices Public Offering of Notes for USD2 Billion 24
  • 2.4.5 Nestle Health Science Enters into Licensing Agreement with Seres Therapeutics 24
  • 3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 26
  • 3.1 Pharmaceuticals & Healthcare, Global, M&A, Q1 2016 26
  • 3.1.1 Top M&A Deals in Q1 2016 27
  • 3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q1 2015 - Q1 2016 28
  • 3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q1 2016 29
  • 3.2.1 Top Initial Public Offerings in Q1 2016 30
  • 3.2.2 Top Secondary Offerings in Q1 2016 31
  • 3.2.3 Top PIPE Deals in Q1 2016 31
  • 3.2.4 Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q1 2015-Q1 2016 32
  • 3.2.5 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q1 2015 - Q1 2016 32
  • 3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q1 2016 34
  • 3.3.1 Top Venture Financing Deals in Q1 2016 35
  • 3.3.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q1 2016 36
  • 3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q1 2016 37
  • 3.3.4 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q1 2015 - Q1 2016 38
  • 3.3.5 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Q1 2015 - Q1 2016 39
  • 3.3.6 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q1 2015 - Q1 2016 40
  • 3.4 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q1 2016 41
  • 3.4.1 Top Private Equity Deals in Q1 2016 42
  • 3.4.2 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q1 2015 - Q1 2016 43
  • 4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q1 2016 44
  • 4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q1 2016 44
  • 4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q1 2015 - Q1 2016 46
  • 4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2016 47
  • 4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q1 2016 48
  • 4.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q1 2016 48
  • 4.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q1 2016 49
  • 4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2015 - Q1 2016 50
  • 4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q1 2015 - Q1 2016 52
  • 4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q1 2015 - Q1 2016 53
  • 4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2015 - Q1 2016 55
  • 5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q1 2016 57
  • 5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q1 2016 57
  • 5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2015 - Q1 2016 59
  • 5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q1 2016 60
  • 5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q1 2016 61
  • 5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q1 2016 61
  • 5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q1 2015 - Q1 2016 62
  • 5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q1 2015 - Q1 2016 63
  • 5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q1 2015 - Q1 2016 65
  • 5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q1 2015 - Q1 2016 66
  • 5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q1 2015 - Q1 2016 68
  • 6 Pharmaceuticals & Healthcare, Global, M&A Financial Analysis 70
  • 6.1 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value versus Median Deal Value, Q1 2015 - Q1 2016 70
  • 6.2 Pharmaceuticals& Healthcare, Global Acquisitions, Average Price Earnings of Acquired Companies, Q1 2015 - Q1 2016 72
  • 6.3 Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q1 2015 - Q1 2016 73
  • 6.4 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q1 2015 - Q1 2016 74
  • 6.5 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Market Price Per Share, Q1 2015 - Q1 2016 75
  • 6.6 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q1 2015 - Q1 2016 76
  • 7 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 77
  • 7.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q1 2016 77
  • 7.1.1 Oncology - Deals of the Quarter 79
  • 7.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q1 2016 81
  • 7.2.1 Central Nervous System - Deals of the Quarter 82
  • 7.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q1 2016 84
  • 7.3.1 Infectious Disease - Deals of the Quarter 85
  • 7.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q1 2016 88
  • 7.4.1 Immunology - Deals of the Quarter 89
  • 7.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q1 2016 91
  • 7.5.1 Metabolic Disorders - Deals of the Quarter 92
  • 7.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q1 2016 94
  • 7.6.1 Cardiovascular - Deals of the Quarter 96
  • 7.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q1 2016 98
  • 7.7.1 Gastrointestinal - Deals of the Quarter 99
  • 7.8 Pharmaceuticals & Healthcare, Global, Hematological Disorders Deals, Q1 2016 101
  • 7.8.1 Hematological Disorders - Deals of the Quarter 102
  • 7.9 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q1 2016 104
  • 7.9.1 Respiratory - Deals of the Quarter 105
  • 7.10 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q1 2016 107
  • 7.10.1 Dermatology - Deals of the Quarter 108
  • 8 Deal Summary by Geography 110
  • 8.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q1 2016 110
  • 8.1.1 North America - Deals of the Quarter 112
  • 8.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q1 2016 113
  • 8.2.1 Europe - Deals of the Quarter 114
  • 8.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q1 2016 118
  • 8.3.1 Asia-Pacific - Deals of the Quarter 119
  • 8.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q1 2016 121
  • 8.4.1 Rest of the World - Deals of the Quarter 122
  • 9 Pharmaceuticals & Healthcare, Global, Top Advisors 124
  • 9.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Q1 2015 - Q1 2016 124
  • 9.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Q1 2015 - Q1 2016 126
  • 10 Appendix 127
  • 11 Further Information 129
  • 11.1 Methodology 129
  • 11.2 About GlobalData 130
  • 11.3 Disclosure information 131
  • 11.4 Disclaimer 131
  • Deal Values in Pharmaceutical & Healthcare Industry Decreased in Q1 2016

    GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2016” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&A) and financing in the pharmaceutical and healthcare market. The report provides detailed information on partnerships, licensing agreements, M&As, equity/debt offerings, private equity and venture financing transactions registered in the pharmaceutical and healthcare industry in Q1 2016. The report presents detailed comparative data on the number of deals and their value in the past five quarters subdivided into deal types, segments, and geographies. The report also offers information on the top venture capital and advisory firms in the pharmaceutical and healthcare industry.

    GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database and through primary and secondary research.

    Deal Value Of M&A’s Decreased In Q1 2016

    Merger and acquisition (M&A) deals, including asset purchases, recorded a decrease in the number of deals and deal values in Q1 2016 with 132 deals worth USD56.8 billion, compared to 252 deals worth USD101.3 billion in Q1 2015. On a quarter-on-quarter basis, the number of deals decreased and deal values increased in Q1 2016, compared to 167 deals worth USD27.9 billion in Q4 2015.

    The oncology therapeutics market accounted for the majority of M&As with 164 deals worth USD150.8 billion between Q1 2015 and Q1 2016. Central nervous system therapeutics market followed in second place with 161 deals worth USD120.3 billion.

    Partnerships Increased In Q1 2016

    Partnerships reported an increase in the number of deals and a decline in deal values with 287 deals worth USD7 billion in Q1 2016, compared to 226 deals worth USD8.3 billion in Q1 2015. On a quarter-on-quarter basis, the number of partnerships and their values decreased in Q1 2016, compared to 322 deals worth USD4 billion in Q4 2015.

    Pharmaceutical and healthcare companies entered into 175 partnerships for Preclinical stage products, which accounted for 34% of the deals from Q1 2015 to Q1 2016. Products in Phase II stage stood second with 98 deals, which accounted for 19% of the deals.

    The oncology therapeutics market stood at the top in the pharmaceutical and healthcare industry with 423 partnerships worth USD16.1 billion between Q1 2015 and Q1 2016. The central nervous system therapeutics market followed with 154 deals worth USD3.9 billion in the same period.

    Licensing Deals Repoted A Decline In Q1 2016

    Licensing agreements reported a decrease in the number of deals and an increase in deal values in Q1 2016 with 145 deals worth USD9.3 billion in Q1 2016, as compared to 175 deals worth USD8.8 billion in Q1 2015. On a quarter-on-quarter basis, the number of licensing deals increased and their values decreased in Q1 2016, compared to 140 deals worth USD16 billion in Q4 2015.

    Licensing agreements recorded an increase in upfront payments and a decline in milestone payments in Q1 2016. A total of USD1.3 billion and USD4.1 billion were reported as upfront and milestone payments in Q1 2016, compared to USD511.1m and USD6.2 billion, respectively in Q1 2015. On a quarter-on-quarter basis, upfront payments and milestone payments decreased in Q1 2016, compared to USD1.8 billion and USD12.7 billion, respectively, in Q4 2015.

    In licensing by phase, products in Preclinical stage recorded 128 deals, which accounted for 30% of the total deals between Q1 2015 and Q1 2016. In second place, products in Phase II accounted for 20% of the deals.

    Venture Capital Investments Decreased In Q1 2016

    The venture capital (VC) segment reported 195 deals worth USD3.1 billion in Q1 2016, as compared to 215 deals worth USD3.5 billion in Q1 2015. On a quarter-on-quarter basis, the number of VC deals increased and their values decreased marginally in Q1 2016, compared to 181 deals worth USD3.2 billion in Q4 2015.

    Orbimed Advisors, LLC topped the list of venture financing firms by participating in 28 transactions worth USD1.3 billion in the last five quarters (Q1 2015 - Q1 2016).

    Deals In North America Reported A Decrease In Q1 2016

    North America recorded a decrease in the number of deals and deal values in Q1 2016. The region registered 669 deals worth USD66.4 billion in Q1 2016, compared to 818 deals worth USD154 billion in Q1 2015. On a quarter-on-quarter basis, the number of deals decreased and deal values increased in Q1 2016, when compared to 677 deals worth USD47.7 billion in Q4 2015.

    Europe recorded a decrease in the number of deals and deal values in Q1 2016 with 332 deals worth USD27.5 billion, as compared to 422 deals worth USD65.7 billion in Q1 2015. On a quarter-on-quarter basis, the number of deals and deal values decreased in Q1 2016, when compared to 367 deals worth USD34.9 billion in Q4 2015.

    Asia Pacific recorded a decrease in the number of deals and deal values in Q1 2016. The region reported 202 deals worth USD13.1 billion in Q1 2016, as compared to 227 deals worth USD17.9 billion in Q1 2015. On a quarter-on-quarter basis, the number of deals and deal values decreased in Q1 2016, when compared to 260 deals worth USD26.6 billion in Q4 2015.

Please select a license type

Share

Related Products

GlobalDataPartnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2016Product ThumbnailPartnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2016, Industry ReportProduct #: 497061
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved